Ketoprofen ext-rel Caps Rx
Generic Name and Formulations:
Ketoprofen 200mg; ext rel; pH-dependent coated pellets in caps.
Various generic manufacturers
Indications for Ketoprofen ext-rel Caps:
Osteoarthritis. Rheumatoid arthritis.
Aspirin allergy. Late pregnancy. Coronary artery bypass graft surgery.
Advanced renal disease: not recommended. Acute pain. Renal or hepatic dysfunction. Edema. Hypertension. Cardiac failure. History of upper GI disease. Bleeding disorders. Hypoalbuminemia. Monitor blood, hepatic, renal, and ocular function in chronic use. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
NSAID (propionic acid deriv.).
Avoid salicylates, probenecid. Renal toxicity potentiated with diuretics. Monitor oral anticoagulants. May increase toxicity of methotrexate. May increase serum lithium levels.
GI bleeding, peptic ulcer, peripheral edema, dyspepsia, headache, dizziness, drowsiness, nausea, abdominal pain, diarrhea, constipation, flatulence, rash (discontinue if occurs), tinnitus, visual disturbances, GI or CNS disturbances, nephrotoxicity, jaundice. See literature re: risk of cardiovascular events.
Formerly known under the brand name Oruvail.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline